A study of incidence of COVID infection in rheumatologic patients on treatment with targeted therapies (TT) (b and stDMARD and comparison of incidence of such infection in the general population
Latest Information Update: 15 Jan 2021
At a glance
- Drugs Abatacept (Primary) ; Anakinra (Primary) ; Baricitinib (Primary) ; Rituximab (Primary) ; Ustekinumab (Primary) ; Anti-interleukin-6 monoclonal antibody; Tumour necrosis factor inhibitors
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 15 Jan 2021 New trial record